

# Docking-based virtual screening and pharmacophore analysis of novel GH-20 $\beta$ -N-acetylglucosaminidase inhibitors

Grittin Phengsakun <sup>1</sup>, Bundit Boonyarit <sup>2</sup> and Wipa Suginta <sup>1, \*</sup>


<sup>1</sup> School of Biomolecular Science and Engineering (BSE), Vidyasirimedhi Institute of Science and Technology (VISTEC), Payupnai, Wangchan, Rayong 21210, Thailand

<sup>2</sup> School of Information Science and Technology (IST), Vidyasirimedhi Institute of Science and Technology (VISTEC), Payupnai, Wangchan, Rayong 21210, Thailand

\* Correspondence: wipa.s@vistec.ac.th

**Abstract:** GH-20  $\beta$ -N-Acetylglucosaminidases (GlcNAcase) is a promising target for the development of new drugs active against *Vibrio* infections since the suppression of GH-20 GlcNAcase activity can lead to the inhibition of *Vibrio* spp. growth. In this study, we set up a virtual screening for potential GH-20 GlcNAcase inhibitors from the Reaxys commercial database, using a known active compound (Redoxal) as a ligand search model and GlcNAcase from *V. harveyi* (VhGlcNAcase) as a protein search model. Virtual screening results identified the top ten compounds, with ChemPLP scores between 98.27 and 104.15. All ten compounds had scores greater than those of Redoxal (85.74) and the natural substrate (GlcNAc)<sub>4</sub> (85.40). Interactions and pharmacophore analysis indicated that W582 is a key residue that interacts with all the identified molecules, mainly by  $\pi$ -stackings interactions. The inner part of all ten molecules is located at subsite -1, deep in the catalytic pocket of VhGlcNAcase, while the outer part stretches beyond the binding pocket. Hit compounds identified in this study may serve as potential candidates for further development of new, highly potent anti-microbial agents for controlling *Vibrio* spp. infections in both aquaculture and humans.

## Graphical abstract:



**Copyright:** © 2021 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

**Keywords:** Virtual screening; Molecular docking;  $\beta$ -N-acetylglucosaminidases; VhGlcNAcase; GH-20 GlcNAcases inhibitors; Protein-drug interactions

**Funding:** This research was funded by Vidyasirimedhi Institute of Science and Technology (VISTEC), grant number 600/111411/001920302000

**Acknowledgments:** We acknowledge the computer resource support by School of Information Science and Technology (IST), Vidyasirimedhi Institute of Science and Technology (VISTEC) for used in virtual screening.

**Conflicts of Interest:** The authors declare no conflict of interest.